US EditionStudy Finds Genetic Basis for GLP-1 Weight Loss Efficacy and Side Effects
The study found GLP1R and GIPR variants that help explain why patients lose 6% to 20% of starting weight or develop nausea, researchers said.
- On Wednesday, 23andMe Research Institute published a study in Nature identifying genetic predictors for GLP-1 weight loss efficacy and side effects.
- Researchers utilized data from 27,885 individuals to identify specific gene variants in GLP1R associated with weight loss and GIPR linked to medication-related nausea.
- Noura Abul-Husn, Chief Medical Officer at 23andMe Research Institute, announced a new Total Health report with an interactive tool helping members explore personalized GLP-1 outcomes.
- Genetic effects remain modest, with differences of less than 1kg per allele, while drug-specific effects and other factors drive the majority of treatment variability.
- Marie Spreckley, Research Programme Manager at the University in Cambridge, stated current evidence is insufficient to guide routine clinical treatment decisions despite advancing scientific understanding.
14 Articles
14 Articles
Genetics may help explain why some people don't lose much weight using GLP-1 drugs
Genetic variants may help explain why some people have more success using GLP-1 weight-loss drugs than others, a new study found. Two specific variants are tied to greater weight loss and increased vomiting and nausea.
Genetic predictors for GLP-1 weight loss efficacy and side effects identified
23andMe Research Institute, a nonprofit medical research organization, announced the publication of a study that identifies genetic predictors for GLP-1 weight loss efficacy and side effects. GLP-1 receptor agonists, including semaglutide and tirzepatide, have transformed the clinical management of weight and obesity. However, patients experience substantial variability in both weight loss efficacy and the incidence of side effects. Some individ…
St Catharines Standard
New 23andMe Research Institute Study Identifies Genetic Predictors for GLP-1 Weight Loss Efficacy and Side Effects
PALO ALTO, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- 23andMe Research Institute, a nonprofit medical research organization, announced the publication of a study that identifies genetic predictors for GLP-1 weight loss efficacy and side effects.
Coverage Details
Bias Distribution
- 55% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
